

Resource Summary Report

Generated by [NIF](#) on Aug 9, 2026

Hepa 1-6

RRID:CVCL_0327

Type: Cell Line

Proper Citation

Ubigen Cat# YC-A005, RRID:CVCL_0327

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0327

Proper Citation: Ubigen Cat# YC-A005, RRID:CVCL_0327

Description: Cell line Hepa 1-6 is a Cancer cell line with a species of origin Mus musculus (Mouse)

Sex: Female

Disease: Hepatocellular carcinoma of the mouse

Defining Citation: [PMID:11004682](#), [PMID:12606785](#), [PMID:25193168](#), [PMID:26280412](#), [PMID:28152020](#), [PMID:31220119](#)

Comments: Characteristics: Secretes several liver products including albumin, alpha-fetoprotein, alpha 1-antitrypsin and amylase (ECACC=92110305).

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: Hepa 1-6

Synonyms: HEPA 1-6, Hepa-1-6, Hepa1-6

Cross References: BTO:BTO_0002895, CLO:CLO_0003711, CLO:CLO_0050769, EFO:EFO_0022833, MCCL:MCC:0000223, CLDB:cl1658, CLDB:cl1659, CLDB:cl5199, AddexBio:C0015005/4999, ATCC:CRL-1830, BCRC:60051, BioSample:SAMN11397636, CCRID:1101MOU-PUMC000106, CCRID:3101MOUSCSP512, CCRID:3101MOUTCM39, CCRID:4201MOU-CCTCC00313, CCRID:6101MOU-CERC000105, CCTCC:GDC0313, CLS:400474, DSMZ:ACC-175, DSMZCellDive:ACC-175, ECACC:92110305, GEO:GSM1374085, GEO:GSM1374086, GEO:GSM1374087, GEO:GSM1374088, GEO:GSM1374089, GEO:GSM1374090, IZSLER:BS TCL 157, Lonza:830, NCBI_Iran:C517, PRIDE:PXD000666, PRIDE:PXD001792, RCB:RCB1638, Ubigen:YC-

A005, Wikidata:Q54882820

ID: CVCL_0327

Vendor: Ubigene

Catalog Number: YC-A005

Hierarchy: cvcl_s550

Record Creation Time: 20250130T071625+0000

Record Last Update: 20260809T004351+0000

Ratings and Alerts

No rating or validation information has been found for Hepa 1-6.

No alerts have been found for Hepa 1-6.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 792 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Yu S, et al. (2026) Hepatic Stellate Cell-Specific METTL3 Deficiency Promotes Hepatocellular Carcinoma Progression via BMP10-SMAD1/5/8 Signaling. Cancer research communications, 6(5), 1109.

Kong L, et al. (2026) Radiation-Enhanced CD24 Membrane Trafficking via GPI Anchoring Mediates Antitumor Immune Evasion. Cancer research, 86(6), 1480.

Zeng Q, et al. (2026) Intratumoral Tertiary Lymphoid Structures Characterized by a B Cell-Related Signature Elicit Antitumor Effect through HAPLN3 in Hepatocellular Carcinoma. Cancer immunology research, 14(5), 771.

Guo Z, et al. (2026) RASGEF1B suppresses hepatocellular carcinoma through the ALDH7A1/Betaine/SNAI1 metabolic/epigenetic axis. Journal of translational medicine, 24(1).

Li Y, et al. (2026) Tumor-Intrinsic ARHGEF3 Enhances Antitumor Immunity by Promoting T-Cell Infiltration and Limiting Myeloid Cell-Mediated Immunosuppression. Advanced science (Weinheim, Baden-Wuerttemberg, Germany), 13(38), e23895.

Liu Y, et al. (2026) Hepatitis B virus promotes hepatocellular carcinogenesis by activating IL-6-dependent tumor-macrophage crosstalk and M2-like macrophage polarization. The

Journal of biological chemistry, 302(8), 113283.

Bi B, et al. (2026) MCT8 Modulates Metabolite Uptake and T-cell Exhaustion to Promote Immunosuppression and Tumor Progression in Hepatocellular Carcinoma. *Molecular cancer therapeutics*, 25(5), 771.

Liu Z, et al. (2026) AARS1-mediated AKR1B10 lactylation stabilizes an aerobic glycolysis-positive feedback loop to drive lenvatinib resistance in hepatocellular carcinoma. *Clinical and translational medicine*, 16(1), e70561.

Jiang X, et al. (2026) Targeting Circulating FABP4 Ameliorates Obesity-Associated Hepatic Steatosis. *bioRxiv : the preprint server for biology*.

Weerasopon K, et al. (2026) Loss of Ezh2 promotes M2-like macrophage polarization in hepatocellular carcinoma. *iScience*, 29(4), 115180.

Li L, et al. (2026) Tumor-specific glyco-detonators: A neuraminidase-3-gated programmable DNA Nanoarchitectonics for liver cancer-exclusive chemotherapy. *Journal of controlled release : official journal of the Controlled Release Society*, 390, 114495.

Jia X, et al. (2026) NAD⁺ hydrolysis catalyzed by SeO is required for mitochondrial homeostasis. *Cell*, 189(9), 2633.

Qu C, et al. (2026) Targeted extracellular vesicle-photoimmunotherapy remodels stromal-immune microenvironment to boost chemo-immunotherapy in preclinical models. *Cell reports. Medicine*, 7(7), 102843.

Su LP, et al. (2026) Dual Specificity Phosphatase 4 Enhances Immunotherapy Response by Inhibiting TGF- β 1 Secretion in Hepatocellular Carcinoma. *Cancers*, 18(8).

Gu Y, et al. (2026) Sunitinib induces immunogenic cell death through eIF2 γ phosphorylation to potentiate immunotherapy in HCC. *iScience*, 29(4), 115378.

Hao X, et al. (2026) Engineered CAR-NKT Extracellular Vesicles Suppress Tumor Progression and Enhance Antitumor Immunity. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(13), e21623.

Wang M, et al. (2026) Elemene Augments the Effects of Anti-PD-1 Immunotherapy on Hepatocellular Carcinoma by Regulating the miR-130a-5p/SPP/MHC-I Axis. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(11), e11887.

Yan L, et al. (2026) The Erlin1/2 complex is a dynamic scaffold for membrane microdomain assembly on the endoplasmic reticulum. *Molecular cell*, 86(7), 1362.

Zhao Y, et al. (2026) Physiological respiration pressure-driven piezocatalytic therapy for malignant ascites with a gold-core magnified mesoporous piezoelectric nanoplateform. *Biomaterials*, 333, 124233.

Xu M, et al. (2026) UFMylation Suppresses Hepatocellular Carcinoma Metastasis by Inhibiting β -Catenin-Driven Hybrid EMT and NK Cell Evasion. *Cancer research*, 86(13), 3213.